Anwita Biosciences Pipeline
| Drug | Indication | Phase |
|---|
| AWT020 | NSCLC, GI and gynecological cancers | Phase 1 |
| AWT026 | Melanoma (combo with aPD-1; CAR-T) | Preclinical |
| JS212 | NSCLC; CRC | Lead Optimization |
| AWT041 | Solid tumors | IND Enabling |
| AWT032 | Hematological autoimmune disease | Lead ID |
| AWT038 | Cancer Cachexia (Solid tumors) | Preclinical |